GS 4774

Drug Profile

GS 4774

Alternative Names: GI 13020; GS-4774; Inactivated recombinant Saccharomyces cerevisiae expressing Hepatitis B virus X, surface and core antigens (GI-13020); Tarmogen T cell immunity stimulator

Latest Information Update: 22 Nov 2016

Price : $50

At a glance

  • Originator GlobeImmune
  • Developer Gilead Sciences
  • Class Hepatitis B vaccines
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Hepatitis B

Most Recent Events

  • 17 Nov 2016 Gilead Sciences terminates its licence for GS 4774 and returned the rights to GlobeImmune
  • 16 Mar 2016 GlobeImmune completes enrolment in its phase II trial for Hepatitis B infections (Combination therapy) in US, Canada, New Zealand, Romania, South Korea and Italy
  • 27 May 2015 Efficacy and adverse events data from a phase II trial in Hepatitis B released by GlobeImmune
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top